Navigation Links
Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial
Date:9/27/2011

OXFORD, England, September 27, 2011 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical results showing that its ToleroMune® hay fever vaccine substantially improved patients' allergy symptoms compared with those on placebo.  The treatment was extremely well tolerated.  

During the randomised, double-blind, placebo-controlled phase II study conducted in 50 hay fever sufferers in Quebec, Canada, patients received four doses from one of five different treatment regimes over a 12-week period.  Five weeks later, investigators tested the patients' skin and eye responses to grass pollen.  The results show that the treatment reduced allergic symptoms in patients' eyes by up to 30% more than placebo.  In addition, the therapy improved early and late skin reactions by up to 54% and 19% above placebo respectively.  The ToleroMune T-cell vaccine had a similar safety profile to placebo.

Following these results, Circassia has initiated the final phase II trial of its hay fever treatment.  The double-blind, placebo-controlled study is underway in Kingston, Canada in 280 volunteers, and will assess the effectiveness of the ToleroMune T-cell vaccine at improving patients' nasal symptoms and eye responses when exposed to grass pollen in an exposure chamber.  

"Achieving these clinical results is particularly encouraging as hay fever is an extremely common allergy, which can have a major impact on sufferers," said Steve Harris, Circassia's CEO.  "Many current therapies provide short-term symptom relief only, while traditional immunotherapies can require specialist treatment over several years to address the underlying disease.  Circassia's latest results follow earlier successful studies in a range of different allergies.  Our clinical data show that Circassia's T-cell vaccines have the potential to revolutionise allergy therapy, and these recent results give us the confidence to proceed with the final phase II testing of our unique hay fever treatment."

About Circassia's allergy T-cell vaccines

Circassia is developing a range of allergy T-cell vaccines based on its proprietary ToleroMune® technology.  The company has successfully completed a number of phase II studies with its cat, house dust mite, ragweed and grass allergy therapies.  Clinical results show that short treatment regimes with Circassia's T-cell vaccines can greatly reduce patients' allergic responses, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated.  As a result, the treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  Over 150 million people suffer from allergic rhinitis in the US and Europe, and approximately 15% - 25% of people in these countries are sensitive to grass pollen.  As a result, the current allergy treatment market is valued at approximately $12 billion per year.  

About Circassia

Circassia was founded in 2006 by a team of highly experienced biotechnology scientists and entrepreneurs, and is chaired by the former Chairman of GlaxoSmithKline, Sir Richard Sykes.  The company is based in the UK on the Oxford Science Park, and in Hamilton, Canada, where its joint venture Adiga Life Sciences is located.  Its ToleroMune technology was developed originally by scientists at Imperial College, London.  Having successfully completed four fundraising rounds, Circassia has raised approximately £93 million ($159 million) and is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations and Invesco Perpetual.

Contacts
Steve Harris
CEO
Circassia
Tel: +44 (0)1865 784574
http://www.circassia.co.uk

Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241



'/>"/>
SOURCE Circassia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection
2. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
5. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
6. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
7. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
8. The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics: October 6, 2011, 1 PM EDT, Webinar
9. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
10. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
11. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology:
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):